Abstract
The APOBEC3 (A3) proteins are host antiviral cellular proteins that hypermutate the viral genome of diverse viral families. In retroviruses, this process requires A3 packaging into viral particles1–4. The lentiviruses encode a protein, Vif, that antagonizes A3 family members by targeting them for degradation. Diversification of A3 allows host escape from Vif whereas adaptations in Vif enable cross-species transmission of primate lentiviruses. How this ‘molecular arms race’ plays out at the structural level is unknown. Here, we report the cryogenic electron microscopy structure of human APOBEC3G (A3G) bound to HIV-1 Vif, and the hijacked cellular proteins that promote ubiquitin-mediated proteolysis. A small surface explains the molecular arms race, including a cross-species transmission event that led to the birth of HIV-1. Unexpectedly, we find that RNA is a molecular glue for the Vif–A3G interaction, enabling Vif to repress A3G by ubiquitin-dependent and -independent mechanisms. Our results suggest a model in which Vif antagonizes A3G by intercepting it in its most dangerous form for the virus—when bound to RNA and on the pathway to packaging—to prevent viral restriction. By engaging essential surfaces required for restriction, Vif exploits a vulnerability in A3G, suggesting a general mechanism by which RNA binding helps to position key residues necessary for viral antagonism of a host antiviral gene.
Subject terms: Virus-host interactions, Retrovirus, Cryoelectron microscopy, Restriction factors
The authors report the cryo-EM structure of human A3G bound to HIV-1 Vif, and the hijacked cellular proteins that promote ubiquitin-mediated proteolysis, suggesting how Vif antagonizes A3G by intercepting it to prevent viral restriction.
Main
The APOBEC3 (A3) proteins are host cytosine deaminases with the capacity to mutate viral genomes across many different viral families (reviewed in refs. 5–7). APOBEC3G (A3G), in particular, is a powerful restriction factor of retroviruses that blocks viral replication by hypermutation of viral complementary DNA and inhibition of reverse transcription1–3. A3G is packaged into retroviral capsids through interactions with viral genomic RNA during assembly, exerting its antiviral activity inside the capsid where reverse transcription occurs during infection8–12. The lentiviral protein Vif inhibits A3G packaging into virions by targeting it for ubiquitin-mediated proteolysis, and through ubiquitin-independent mechanisms that are poorly understood13–17. On a long evolutionary timescale, A3G has undergone diversifying selection to escape antagonism by Vif whereas adaptations in Vif allow primate lentiviruses to expand their host range and adapt to host polymorphisms18,19. Repeated bouts of diversifying selection and adaptation are referred to as ‘molecular arms races’20. Adaptations in the Vif protein encoded by an SIV that infects red-capped mangabey monkeys (SIVrcm) to antagonize the hominid version of A3G enabled cross-species transmission of a lentivirus from monkeys to chimpanzees, which underlies the ancient origin of HIV-1 and the AIDS pandemic21. Although it is commonly assumed that sites of molecular arms races report on direct protein interactions, physical evidence of this interaction site to explain the mechanisms of how Vif promotes processive ubiquitination on A3G, and how mutations in Vif or A3G promote host escape and viral adaptation, remain critical and unresolved questions.
The A3 proteins are comprised of either one or two cytidine deaminase domains (CDAs) among which A3D, A3F and A3G (containing double-domains CDA1 and CDA2) and single-domain A3H inhibit replication of primate lentiviruses. To target A3 family members for ubiquitination and degradation, Vif hijacks a host Cullin-RING ubiquitin ligase (CRL) complex and a transcription cofactor core-binding factor beta (CBFβ)16,22,23. Costructures of Vif with full-length A3 family members have been a major challenge for the field due to poor solubility and difficulty in obtaining homogenous protein for structural studies. Accordingly, extensive effort has been devoted to the generation of variant A3 proteins that are soluble and amenable to structural studies24–27. For example, a 3.9 Å cryogenic electron microscopy (cryo-EM) structure of a solubility-optimized variant of A3F-CDA2 covalently fused to CBFβ bound to the Vif α/β domain showed an electrostatic interface required for viral infectivity27. However, the interaction of CDA2 of A3F with Vif and CBFβ is weak, and the importance of the tetramer comprising A3F-CDA2, the Vif α/β domain and CBFβ protomers for A3 antagonism is unclear27–29; moreover, the well-characterized evolutionary adaptations in A3 proteins in response to Vif occur in the CDA1 of A3G19,30, leaving substantial gaps in our knowledge of molecular mechanisms of Vif antagonism of A3 proteins and molecular arms races between them.
Here, we solved the structure of wild-type human A3G bound to the substrate receptor module of CRL5 containing HIV-1 Vif, CBFβ, Elongin B and Elongin C (VCBC) using single-particle cryo-EM (Extended Data Table 1 and Extended Data Figs. 1–4). Two-dimensional (2D) classification indicates that the complex is a dimer of A3G–VCBC protomers (Extended Data Fig. 1c). Our highest-resolution map, generated by focused refinement around the monomer structure of A3G–VCBC, will be presented first, followed by the structures of the dimer (Methods, Fig. 1a,b and Extended Data Fig. 2).
Extended Data Table 1.
RNA bridges the Vif–A3G interaction
The crystal structure of VCBC and the AlphaFold2-predicted model of human A3G could be readily fit into a 2.7 Å-resolution map of the A3G–VCBC monomer (Fig. 1a,b)31. Unexpectedly, well-resolved density was observed for a single-stranded RNA (ssRNA) molecule sandwiched between A3G and Vif, most probably originating from the insect cells in which A3G–VCBC was co-expressed (Fig. 1a,b). Four nucleotides (named NT1–4) of ssRNA are wedged deeply between A3G and Vif, with RNA forming a sharp turn mediated by a hydrogen bond between ribose 2′ hydroxyl of NT2 and the phosphate backbone of NT4 (Fig. 1c,d). The majority of the interactions between A3G and Vif are mediated by CDA1, consistent with previous studies indicating that it binds RNA and is necessary and sufficient for binding to Vif11,12,24,32–35.
RNA binding has been implicated in the regulation of cytoplasmic localization, self-association and packaging of A3G into HIV-1 virus, which is essential for its antiviral activity12,36–38. The A3G CDA1 and CDA2 domains sandwich the RNA tetranucleotide at the interface formed by Vif helix 1 (residues 15–30), strand 2 (residues 39–41) and a 310 helix (residues 42–46) (Fig. 1b–d). There is a division of labour between A3G and Vif in recognizing RNA. The bases of NT1–3 are bound to A3G, with aliphatic interactions, aromatic base stacking and hydrogen bonds to NT1 and NT2 typical of sequence-specific interactions (Fig. 1e). For example, the purine base of NT1 is buried in a junction formed by CDA1 (I26 and W127), CDA2 (K270) of A3G and Vif (H42, H43 and Y44), forming a hydrogen bond with the main-chain carbonyl of F268 on CDA2 (Fig. 1e). These interactions may explain why Vif residues lining the surface of the 310 helix are important for A3G degradation and viral infectivity35,39–44. The purine base of NT2 is buried in a hydrophobic pocket formed by A3G residues (I26, W94, Y124, Y125 and W127) interacting with Y125 by T-stacking; NT2 also forms a hydrogen bond with the main-chain amide of Y125 and the carbonyl of P25 and L123 (Fig. 1e). Based on hydrogen bonding patterns, NT1 and NT2 are probably adenine. Sequence-specific interactions of NT1 and NT2 with A3G are consistent with the enrichment of purine-rich motifs that interact with A3G in cells and virions of vif-deficient HIV-1 (ref. 45). Both this result and our structure suggest that A3G bound to purine-rich RNA is the substrate of the Vif E3 ligase.
In contrast to sequence-specific interactions with purine NT1 and NT2 with A3G, NT3 and NT4 are stabilized by aromatic stacking interactions with Y59 of A3G and Y30 of Vif, respectively (Fig. 1e). A composite binding site for the RNA backbone is formed by Vif and A3G. Buried phosphates of NT2 and NT3 are stabilized by hydrogen bonds and salt bridges with Vif (residues Y40, K22 and K26) and A3G (Y124 and Y125), respectively (Fig. 1e). Almost all of the key contacts in the A3G–RNA–VCBC monomer interface have been mutated in previous genetic studies and result in a loss of Vif function (Supplementary Tables 1 and 2), which validates their importance in our structure.
Because amino acids at positions 22, 23, 26 and 40 of Vif make exclusive interactions with RNA, we substituted them with different classes of amino acid to test the role of RNA in Vif-mediated antagonism of A3G (Fig. 1e,f). Substitution of K26 was not tolerated, supporting its role in coordination of multiple interactions with the phosphate backbone of NT2 and NT4. By contrast, K22 and S23 were tolerant of polar amino acids but refractory to nearly all aromatic and aliphatic substitutions, consistent with their role in coordinating the phosphate backbone of NT2 and NT4 (Extended Data Fig. 5). The partial loss of function of Vif substitutions at Y40 may reflect the dual role of this residue, which interacts with RNA (NT2) and the 310 helix of Vif. These functional results are largely reflected in the evolutionary constraints on Vif in HIV-1 and SIV sequences. For example, there is perfect conservation at residue 26 in HIV-1 and SIVcpz sequences whereas the only amino acids represented at position 22 are asparagine, lysine and threonine (Fig 1f and Extended Data Fig. 5a). These positions are also enriched with polar (residue 40) or charged (residues 22 and 26) amino acids in more divergent SIV Vif sequences, suggesting that the binding mode for A3G, RNA and Vif is deeply conserved (Extended Data Fig. 5). These results suggest that interaction of Vif with RNA is required for the antagonism of A3G. We conclude that RNA functions as a ‘molecular glue’ to stabilize Vif–A3G interactions, much like hormones or small molecules act to recruit substrates to cellular ubiquitin E3 ligase complexes46,47.
Evolution of the Vif–A3G interface
The identity of residues 128 and 130 in A3G has previously been shown to determine the species specificity of the adaptation of Vif to a new host species (reviewed in refs. 30,48). Here we call this interface with Vif the ‘arms race interface’, which has undergone diversifying selection during primate evolution19,21,49. The arms race interface is comprised exclusively of protein interactions between A3G and Vif and is adjacent to the RNA interface (Fig. 2a). Residues D128 and D130 of A3G are buried deep in the arms race interface, forming a network of hydrogen bonds with R15 and Q83 of Vif, respectively (Fig. 2b). Q83 of Vif was previously shown to be essential for the Vif adaptation that allowed cross-species transmission from SIVrcm to chimpanzee50 (Fig. 2b). Furthermore, W70 of Vif interacts closely with W127, D128 and P129 through hydrophobic interactions. This intimate network of contacts explains why lysine substitution at position 128 of A3G, observed in Old World monkeys, is unable to be counteracted by SIVcpz and HIV-1 Vif: it does not contain a hydrogen bond acceptor, nor the charge or shape complementarity to interact with R15 of Vif49,51 (Fig. 2b). R15 and W70 are conserved in all HIV-1 and SIVcpz Vif sequences, consistent with their functioning as lynchpins of the HIV-1 Vif interaction with human A3G (Fig. 2c). However, as predicted from an evolutionarily dynamic interface, the Vif sequences from Old World monkey SIV that must evolve to antagonize divergent host A3G residues in the arms race interface are themselves variable (Fig. 2c and Extended Data Fig. 6a)
Because the Vif gene that gave rise to SIVcpz, and ultimately to HIV-1, is derived from SIVrcm, we asked how the interaction between rcmA3G and Vif at the arms race interface may have evolved21. Comparative modelling of the rcmA3G–Vif complex based on our structure indicates that K128 of A3G directly interacts with Y86 of SIVrcm Vif (equivalent to residue 83 in HIV-1 Vif), suggesting that adaptation of Vif to the positively selected residue 128 entailed a remodelling of interactions occurring at the arms race interface (Extended Data Fig. 6b). We suggest that structural plasticity in Vif enabled amino acid substitutions, such as those occurring at position 86, to neutralize A3G and enable cross-species transmission of SIV from red-capped mangabeys to chimpanzees.
In contrast to the arms race interface, the interface between A3G and Vif that is bridged by RNA is well conserved because residues in the purine-binding pocket of A3G that contact RNA, such as the L7 loop (Y124–W127), are required for restriction in the absence of Vif (NT2; Fig. 1e, Extended Data Fig. 6c and Supplementary Table 2)12. We conclude that Vif binds A3G/RNA in a manner that limits A3G escape over long evolutionary timescales by engaging an essential surface required for antiviral function, explaining why genetic signatures of diversifying selection and adaptation are constrained to the direct protein interactions observed at the molecular arms race interface.
Vif-mediated ubiquitination of A3G
Cullin-RING E3 ligases conjugate ubiquitin onto substrates by orienting acceptor lysines into a ‘ubiquitination zone’ that is accessible by coenzymes52. To determine whether the A3G–RNA–VCBC module is compatible with ubiquitination by CRL5, we used comparative modelling. Lysine residues of A3G that are required for Vif-mediated ubiquitination and subsequent degradation are located within CDA2 of A3G, which is oriented towards the ARIH2 coenzyme of CRL5 that installs the first ubiquitin, allowing extension of K48-linked ubiquitin chains by a ubiquitin-conjugating enzyme53–55 (Fig. 3a). The orientation of CDA2 is determined by intramolecular interactions both in A3G and with Vif and RNA. Within A3G, helix 6 (residues 178–193) of CDA1 forms interactions with CDA2 that fix domain orientations (Fig. 3b) through a salt bridge (K180 with D264) and a series of hydrogen bonds (E191 with Y222, E191 with R238). Aromatic interactions between helix 5 of CDA1 (Y154) and the L3 loop in CDA2 (H250), as well as several hydrophobic contacts between both domains, stabilize CDA domain orientations (Fig. 3b). Interactions between A3G, Vif and RNA may fix the orientation of CDA2 in the three-way interface between K270, Y44 and NT1, respectively, suggesting that RNA not only acts as a molecular glue, but that it may also orient A3G CDA2 acceptor lysines for ubiquitin transfer (Fig. 3b).
Most of the intramolecular interactions in A3G are consistent with the AlphaFold2 structure of human monomeric A3G, but not with previous crystal structures of A3G containing solubility-enhancing mutations or rhesus macaque A3G, which exist in either monomer or self-associated forms25,26. Notably, in the crystal structure of rhesus macaque A3G, helix 6, which was proposed to promote self-association, is buried when human A3G is bound by VCBC26 (Fig. 3b). This observation indicates that VCBC binds A3G in a manner that inhibits its self-association.
Conclusions and implications
Vif and A3G are a paradigmatic example of a host–pathogen molecular arms race. DNA sequence analyses of primate genomes and functional studies show two positions in A3G that undergo diversifying selection allowing escape from antagonists such as Vif18,19. Nevertheless, how Vif binds A3G sufficiently tightly to antagonize A3G remained unclear. We discovered that RNA acts like a molecular glue to promote a high-affinity interaction, because it increases the buried surface area of the Vif–A3G complex and is required for viral infectivity. Our structural studies show a small surface of protein–protein interactions between Vif and A3G that determines cross-species transmissions of primate lentiviruses, as well as the viral adaptations in Vif underlying the origin of HIV-1. Although the buried surface area of the arms race interface is twofold smaller than the RNA interface, it acts as a hot spot controlling the fate of viral infection (Extended Data Fig. 6d).
Previous biochemical and structural studies indicate that A3F-CDA2 makes transient interactions with Vif and CBFβ (refs. 27–29). Our work on wild-type A3G suggests both CDA domains and RNA make stable interactions with Vif without contacting CBFβ. In the former structural study, covalent fusion of A3F-CDA2 and CBFβ was used to increase the occupancy of A3F bound to Vif whereas, in our study, RNA achieves this role by acting as a molecular glue. It is well established that different A3 family members engage surface-exposed residues of Vif that are genetically separable4. We suggest that these surfaces may be bridged by cellular cofactors as described for A3G. An alternative, but not mutually exclusive, possibility is that interactions with Vif are stabilized by bipartite interactions with tandem CDA domains of A3 proteins. Structural studies of Vif–A3 complexes purified after coexpression or native purification from eukaryotic cells will allow this question to be addressed in future studies.
A new model for Vif antagonism of A3G is built on previous functional studies and two key observations from our structure. First, lentiviral genomes are enriched in purines, and cross-linking immunoprecipitation sequencing studies on cells infected with vif-deficient HIV-1 indicate that A3G preferentially binds to purine-rich sequences present in noncoding RNA, messenger RNA and viral genomic RNA45,56. Our structure shows that A3G binds to a purine-rich tetranucleotide motif using residues (Y124–W127) that are essential for viral packaging in the absence of Vif11,12 (Fig. 1c,e). We propose that the substrate of the Vif E3 ligase is not A3G but rather a complex of A3G bound to purine-rich RNA, including purine-rich sequences found in the viral genome.
Second, in addition to RNA binding, A3G self-association is required for its packaging into virions11. Our structure indicates that Vif binding to A3G is mutually exclusive due to its ability to self-associate. Whereas A3G–VCBC forms dimers, within each dimeric assembly A3G forms little or no self-association (Extended Data Figs. 7 and 8 and Supplementary Discussion). This finding suggests that Vif binding to A3G has the capacity to block its packaging independent of ubiquitination activity, a mechanism that may potentiate repression of restriction.
In the absence of Vif, A3G self-associates onto viral genomic RNA and is packaged into viral particles for restriction (Fig. 4). We suggest that Vif antagonizes A3G early in its biosynthesis while it is a monomer in a specific complex with viral genomic RNA en route to viral packaging. Such an early intervention would ensure that Vif counteracts A3G in its most dangerous form for the virus, disrupting encapsidation and promoting polyubiquitination while bound to genomic RNA. Nucleotides that are 3′ to the primary Vif–A3G interaction site may template an additional copy of the Vif E3 ligase to cooperatively reinforce Vif–A3G interactions and ubiquitination (Fig. 4 and Extended Data Fig. 8f). This model is consistent with observations that newly synthesized, low-molecular-mass forms of A3G are packaged and most sensitive to Vif-mediated degradation, explaining ubiquitin-dependent and -independent functions of Vif and how the plasticity of molecular arms races can be enabled by a third party such as RNA.
In summary, A3G binding to Vif is not restricted to the evolutionary dynamic interface subject to diversifying selection and adaptation, contrary to popular models of molecular arms races, but rather also includes a conserved interface through RNA binding that helps position key residues necessary for viral antagonism of a host antiviral gene—a principle that may be adopted by other innate immune proteins and pathogen-encoded antagonists57,58.
Methods
Protein expression and purification
Full-length genes of HIV-1HXB2 Vif, CBFβ, ELOB, ELOC, human A3G with C-terminal Strep-tag and Cullin 5 with C-terminus truncated (1–386; abbreviated as CUL5N) were cloned into a single MacroBac vector, 11A (Addgene, no. 48294) using the restriction-ligation method as previously described59. A recombinant baculovirus encoding all six proteins was generated using the Bac-to-Bac baculovirus expression system (Thermo Fisher Scientific)60. A suspension of Sf9 insect cells was maintained in SF900 III SFM medium (unauthenticated, regularly tested for mycoplasma contamination; Thermo Fisher Scientific, no. 12659017) in a shaker (Innova 4430 incubator shaker) at 120 rpm and 27 °C. Serially diluted recombinant baculoviruses were added to 25 ml of Sf9 cells (2 × 106 cells ml–1) grown in a polycarbonate Erlenmeyer flask (Corning), with protein expression evaluated by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and immunoblotting analysis to optimize the ratio of virus volume to cell volume. One litre of Sf9 insect cells (2 × 106 cells ml–1) was infected with virus at a ratio determined from small-scale titration experiments, and cultured for 48 h before collecting by centrifugation (1,500g, 10 min). Cell pellets were washed with PBS and resuspended in fivefold the pellet volume of lysis buffer (50 mM HEPES, 50 mM NaCl, 5% glycerol, 1% Triton X-100, 5 mM MgCl2, 5 mM CaCl2, 1 mM Tris(2-carboxyethyl)phosphine (TCEP), mini cOmplete protease inhibitor cocktail (Sigma-Aldrich), 25 μg ml–1 DNase I (Sigma-Aldrich) and 50 μg ml–1 RNase A (Sigma-Aldrich), pH 8.0) and lysed by Dounce homogenizer. All purification steps were performed at 4 °C. Cell lysates were clarified by centrifugation at 17,000g (F15-8x50cy rotor) for 2 h. Supernatants were filtered (0.45 μm) and loaded onto a 5 ml StrepTrap HP column (GE Healthcare) pre-equilibrated in binding buffer (50 mM HEPES, 150 mM NaCl, 5% glycerol, 1 mM TCEP, pH 8.0). The column was washed with 15 column volumes (CV) of wash buffer (50 mM HEPES, 1.5 M NaCl, 5% glycerol, 1 mM TCEP, pH 8.0), followed by 5 CV of binding buffer. The protein was eluted in 6 CV of binding buffer supplemented with 5 mM d-desthiobiotin (Sigma-Aldrich). The eluate was dialysed overnight against 1 l of dialysis buffer (50 mM HEPES, 75 mM NaCl, 5% glycerol, 1 mM TCEP, pH 7.0). The sample was applied to a 5-ml HiTrap Heparin column (GE Healthcare) pre-equilibrated with dialysis buffer and eluted over a 0–100% linear gradient of elution buffer (50 mM HEPES, 1 M NaCl, 5% glycerol, 1 mM TCEP, pH 7.0). Fractions containing all six proteins were pooled, dialysed against 1 l of running buffer (30 mM HEPES, 150 mM NaCl, 5% glycerol, 1 mM TCEP) for at least 4 h, loaded onto a Superose 6 increase 10/300 GL column (GE Healthcare) pre-equilibrated with running buffer, and 0.3 ml fractions were collected. Size-exclusion chromatography indicates that the particle is a dimer in solution consisting of two copies of A3G–VCBC–CUL5N (roughly 330 kDa) (Extended Data Fig. 1a). The peak fraction was used directly for cryo-EM without further concentration (Extended Data Fig. 1a,b).
Cryo-EM sample preparation and data acquisition
Purified complex (3.5 μl, 1.9 μΜ) was applied to glow-discharged UltraAuFoil 300 mesh R1.2/1.3 grids (Electron Microscopy Science), incubated for 15 s at 23 °C and 100% humidity, blotted with a blot force of 0 for 12 s then plunge-vitrified into liquid ethane using a FEI Vitrobot Mark IV (Thermo Fisher). A total of 6,429 super-resolution videos were collected at a nominal magnification of ×105,000 on a FEI Titan Krios microscope (Thermo Fisher), equipped with a K3 direct electron detector and BioQuantum energy filter (Gatan) and set to a slit width of 20 eV. Collection was performed semiautomatically using SerialEM at a dose rate of 8.0 e– pixel−1 s−1 for a total dose of 68 e– Å–2 over 118 frames61. Dose-fractionated image stacks were motion corrected, dose weighted and 2× binned to the physical pixel size of 0.835 Å by MotionCor2 in the package SCIPION62,63. A defocus range of −0.8 to −2.0 μm was applied.
Image processing and 3D reconstruction
Initial processing of the resulting summed micrographs was performed in cryoSPARC v.3.0 (ref. 64) (Extended Data Figs. 1 and 2a and Extended Data Table 1). The contrast transfer function (CTF) of dose-weighted, motion-corrected micrographs was estimated by Patch CTF. Micrographs with CTF fit resolution poorer than 4 Å and excessive ice contamination were removed, resulting in a final total of 6,221 micrographs. Selected micrographs were split into two half datasets to speed up data processing. Approximately 2.3 million particles were picked using cryoSPARC circular blob, with a minimum and maximum particle diameter of 150 and 200 Å, respectively, and minimum separation distance between particles of 108 Å, extracted, and 4× binned (3.34 Å per pixel). After 2D classification of extracted particles, class averages without proteinaceous features were discarded. The remaining particles were subjected to two rounds of 2D classification, resulting in classes with clear structural features used to generate a good initial model (Extended Data Fig. 1c). Particles saved from the first round of 2D classification underwent iterative rounds of ab initio reconstruction and heterogeneous refinement using three reference maps (one good and two junk) (Extended Data Fig. 2a). Unbinned particles were re-extracted from the best reconstruction and refined with nonuniform refinement. The resulting three-dimensional (3D) map (designated as ‘consensus reconstruction’) features a well-resolved top body (Extended Data Fig. 2a, black-dashed box) and a bottom body of relatively poor resolution (Extended Data Fig. 2a, red-dashed box).
The top body of the consensus reconstruction map shows visible helical features in which we were able to fit the crystal structure of HIV-1 VCBC (PDB: 4N9F) and the AlphaFold 2-predicted human A3G monomeric structure (AF2: Q9HC16)31,65 (Extended Data Fig. 2a, black-dashed box). To improve the local density of the top body, particle subtraction and focused refinement were applied66. Using Chimera67 and RELION68, a mask was applied to subtract the signal of the bottom body from particle images. These signal-subtracted particles were then reimported into cryoSPARC and subjected to local refinement using a soft mask around the top body. The resulting focused, refined map is termed a ‘monomer’ density map because it accommodates the A3G–VCBC monomer structure well, at a nominal resolution of 2.7 Å (Extended Data Fig. 2b, green box). The local resolution of the density map is variable (Fig. 1a,b and Extended Data Fig. 3). A3G, Vif and CBFβ have well-resolved side-chain density, allowing reliable model building and refinement (Extended Data Fig. 3). The resolution of ELOC and ELOB is sufficient for backbone tracing, but most density for sidechains was absent. CUL5N was present in the preparation but not in our final maps, presumably due to the dynamic features of VCBC–CUL5N or dissociation during freezing15,29.
To address the conformational heterogeneity of the bottom body (Extended Data Fig. 2a, red-dashed box), the 495,571 particles from this consensus refinement were subjected to 3D variability analysis in cryoSPARC69 (Extended Data Fig. 2b). Particles were reclassified into six clusters using three principal components with a soft mask enclosing the bottom body and filter resolution set to 8 Å, followed by nonuniform refinement in cryoSPARC. Four out of six selected classes were then imported into RELION and 3D classification was performed without alignment using a T value of 4 to sort remaining low-quality particles. Classes showing strong density for the bottom body were further processed with 3D autorefine in RELION. The reconstructions showed improved densities in the bottom region, in which three distinct conformational states could be identified at a nominal resolution of 3.3 Å (state 1, 57,207 particles), 3.5 Å (state 1′, 51,055 particles) and 3.46 Å (state 2, 48,310 particles), respectively. The two highest-quality maps (states 1 and 2) were refined further, and the resulting maps allowed fitting of an additional copy of the A3G–VCBC complex (Extended Data Figs. 2b and 7).
Local refinement of state 1 without the top body was performed later in cryoSPARC, leading to a reconstruction with more complete density in this region. The state 2 reconstruction was subjected to a further round of nonuniform refinement in cryoSPARC to improve anisotropy, reaching a nominal resolution of 3.16 Å (Extended Data Fig. 2b). The discrete conformational states of the A3G-VCBC dimer observed with 3D variability analysis were also validated by focused classification in RELION66 (Extended Data Fig. 4). The density of the top body was subtracted from the particle images of the consensus reconstruction (Extended Data Fig. 4a; red-dashed box highlights the density to be retained). These signal-subtracted particle images were classified into six classes without alignment, using a soft mask focused on the bottom body (Extended Data Fig. 4b). Following refinement by 3D autorefine, four out of six selected classes were subjected to 3D classification skipping alignment and 3D autorefinement in RELION. The resulting 3D classes are consistent with those generated by 3D variability analysis in cryoSPARC, differing only in the density levels of the bottom copy. We used the reconstruction maps generated from 3D variability analysis to build the model, owing to their stronger overall density. Postprocessing of the final reconstruction was performed in RELION for estimation of global resolution using a Fourier shell cutoff (FSC) of 0.143 (ref. 70). The maps were sharpened with DeepEMhancer71 and improved by density modification without a model applied in PHENIX72 for map interpretation and model building. Local resolution estimation was done by ResMap73. Directional resolution was assessed using the 3DFSC server74. Format conversion between software was carried out with PyEM75.
Model building and refinement
A comparative model of HIV-1 VifHXB2–CBFβ was built with MODELLER76,77 using the X-ray structure of HIV-1 VifNL4-3CBC–CUL5NTD (PDB code 4N9F) as a template31. The atomic model for hA3G–VHXB2CBC was generated by fitting separate models of human A3G (AF2 code Q9HC16), the aforementioned comparative model of VifHXB2–CBFβ and ELOB/C from the SIVrcm VCBC structure (PDB code 6P59) into the monomer density map using UCSF Chimera50,65,67. This starting model was manually rebuilt in Coot78,79 and adjusted in ISOLDE80 to improve local fitting. The model was then real-space refined in PHENIX81,82. The refined structure obtained from the monomer density map was used as a template for model building of two copies of A3G–VCBC into the EM maps for states 1, 1′ and 2. The same model-building and refinement procedure were performed for states 1 and 2 because of their higher overall resolution. Most residues buried at the A3G–Vif and A3G–A3G interface in the monomer and dimers showed clear density for the side chains, except for Vif residues 117–154 in the bottom copy of state 2 (Extended Data Fig. 3d,e). The weak density in this region precluded precise atomic modelling, and thus the A3G–Vif dimeric interface for state 2 is interpretable on one side only.
After model building the A3G–VCBC proteins, we observed unaccounted-for density sandwiched between A3G and Vif in the EM maps for state 1 and 2 dimers, which was annotated as oligonucleotides by Haruspex, a convolutional neural network trained to detect DNA/RNA versus protein in density maps83. The copurified RNA probably originated from the insect cells where A3G–VCBC was co-expressed. The continuous phosphate backbone density could be traced and well fit with ssRNA. The densities of copurified RNA, especially those sandwiched between A3G and Vif, are clearly resolved, showing features that allow distinguishing of purines and pyrimidines (Fig. 1a–c and Extended Data Fig. 3f). Guided by the EM density of RNA, a dummy sequence containing either adenine or uridine was manually built into the EM map in Coot. RNA geometry was improved by ERRASER84. The complete model, including RNA, was assessed using MolProbity85 and optimized after iterative refinement in Coot and PHENIX. Model–map fit was evaluated by correlation coefficient in PHENIX and Q-score analysis86,87. Protein–RNA interactions were detected by BINANA88 and protein-only interactions were analysed by PLIP89 and Ligplot90 with default settings, except that the hydrogen bond distance cutoff was set to 3.5 Å. Orientation and displacement between state 1 and 2 structures were determined using PyMOL91. The morph video was generated in UCSF Chimera X. Figures 1a–e, 2a,b, 3, as well as Extended Data Figs. 3, 7, 8, were created using Chimera X92. Extended Data Figs. 2, 4 were generated using Chimera67 and Chimera X92. Figure 4 was created using Chimera X92 and BioRender.com. Model statistics are summarized in Extended Data Table 1.
Comparative modelling of rcmA3G–Vif–CBFβ complex
Because the atomic structure of the rcmA3G–Vif complex is not available, we built a comparative model of rcmA3G bound to Vif–CBFβ using MODELLER v.10.1 (refs. 76,77). Sequence identity between the template and model was 79, 40 and 100% for A3G, Vif and CBFβ, respectively. A3G residues required for RNA binding are sequence conserved among hominids and Old World monkeys (Extended Data Fig. 6c). The coordinates of RNA and Zn+2 ions were transferred from the templates to the generated model. After computing around 600 models, we used hierarchical clustering and DOPE scoring to obtain the top-scoring cluster93. The precision of this cluster is 1.4 Å; model precision is defined as the variability among the structural models. The best-scoring model was used for further analysis and is shown in Extended Data Fig. 6b.
Comparative modelling of A3G–Vif–CBFβ–CRL5–NEDD8–ARIH2–Ub
Using MODELLER, we computed a comparative model of the full A3G–Vif–CBFβ in complex with neddylated CRL5 and coenzyme ARIH2. Templates included the A3G–Vif–CBFβ–ELOB/C structure presented here, the Vif–CBFβ–CUL5NTD–ELOB/C pentameric complex (PDB code 4N9F)31, the neddylated CUL5CTD–RBX2–ARIH2 tetrameric complex (PDB code 7ONI)94 and a partial structure containing CUL1–RBX1–Ub–ARIH1 (PDB code 7B5M)52. We computed roughly 100 models, which were clustered and evaluated using DOPE scoring93. The precision of the top-scoring cluster is 1.6 Å. The best-scoring model was used for further analysis and is shown in Fig. 3a.
Assay of vif mutants for A3G degradation
We generated a library of variants at positions 22, 23, 26 and 40 using degenerate oligonucleotide mutagenesis in the HIV-1 LAI vif gene. Individual colonies were sequenced and ligated into a lentiviral vector. Human A3G, flanked by a C-terminal 3XFLAG epitope tag in the pcDNA4/TO vector backbone (Thermo Fisher, no. V102020), was transfected into HEK293T cells (ATCC CRL-3216, unauthenticated, regularly tested for mycoplasma contamination) plated in six-well dishes at a density of 1.5 × 105 cells ml–1. The amount of A3G packaged into virions was assayed by cotransfection of 1,000 ng of Vif vector, 200 ng of A3G-3XFlag and 500 ng of psPAX2 for gag/pol production with TransIT-LT1 transfection reagent (Mirus, no. MIR2304) at a reagent to plasmid DNA ratio of 3:1. Two days post transfection, 1 ml of the supernatant was filtered through a 0.2 μm syringe filter and virions were pelleted in an Eppindorf 5415R tabletop microcentrifuge for 1 h at 4 °C and maximum speed. The supernatant was aspirated off, and 25 μl of NuPAGE 4× loading dye (Invitrogen no. NP0007) was added to each sample. Samples were boiled for 10 min at 95 °C and loaded on an SDS–PAGE gel. Anti-FLAG (Sigma, no. F3164) and anti-p24gag (NIH-ARP, no. 3537) antibodies were used for immunoblotting at a dilution of 1:5,000. Mouse IgG HRP-conjugated antibody (R&D systems, no. HAF007) was used to detect primary antibodies at a dilution of 1:5,000. Chemiluminescent signals from all immunoblots were imaged using the ChemiDocMP imaging system (Bio-Rad), and images were processed with ImageJ software to quantify the densitometry for each detected antibody band. Normalized A3G in virions was calculated by dividing the amount of A3G by that of p24gag and setting that number to 1.0 for the ‘No Vif’ control.
Natural sequence variation analysis
For analysis of natural variation in Vif at interaction sites with RNA and A3G, a curated subtype reference alignment for HIV-1 and SIVcpz sequences was downloaded from the Los Alamos HIV database (https://www.hiv.lanl.gov/content/index). This alignment includes four representatives from each HIV-1 group M subtype and four from groups N, O and P, as well as 21 SIVcpz sequences from each of the Pan troglodytes subspecies (troglodytes and schweinfurthii) sampled from primary isolates comprehensively encompassing the geographic range. Consensus sequences of SIVasc, SIVdeb, SIVdrl, SIVlst, SIVgsn, SIVmac, SIVmus, SIVrcm, SIVsmm, SIVgrv, SIVver, SIVtan, SIVsun, SIVsab and SIVgor were generated from all available sequences in each respective SIV. These sequences were aligned using Clustal Omega, and logo plots were generated from these alignments with WebLogo95.
To generate A3G sequence alignments, sequences were downloaded from NCBI (accession nos. AGI04219.1, AAP85255.1, Q694C1.1, AGE34499.1, NP_001332845.1, XP_011887342.1, AGE34492.1, AGE34504.1, AGE34486.1, AGE34487.1, ANY26448.1, XP_011710628.1, AGX93019.1, XP_011710628.1, AEY75956.1, NP_001279005.2, AEY75955.1, Q7YR25.1). Sequences were aligned with Clustal Omega and visualized using ESPript 3 (ref. 96).
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Online content
Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-023-05779-1.
Supplementary information
Acknowledgements
We thank members of the Emerman, Cheng and Gross laboratories for helpful discussions on this project; D. Bulkley of UCSF Cryo-EM facility for assistance with data collection; S. Gradia of Macrolab for insect cell expression vectors; and A. Manglik of UCSF for advice on model building and refinement. N.M.C. was supported by the University of Washington STD/AIDS Research Training Fellowship (no. NIH/NIAID T32-AI07140) and by a 2021 New Investigator Award from the University of Washington/Fred Hutch Center for AIDS Research (NIH-funded programme under award no. AI027757). C.A.L. was supported by a University of Washington Cellular and Molecular Biology Training Grant (no. T32 GM007270). This work was supported by funding from NIH P50AI150476 and U54AI170792 to M.E., Y.C. and J.D.G.
Extended data figures and tables
Author contributions
Y.L. and J.D.G. conceived the project. J.D.G. supervised the research. Y.-L.L. designed and expressed purified protein complexes, collected and processed cryo-EM data and performed model building and refinement. C.L. developed and performed functional experiments and evolutionary analysis, with supervision from N.M.C. and M.E. C.M.A. trained Y.L.-L. in microscope operation and cryo-EM data acquisition. C.M.A. and Y.C. helped with EM data analysis and interpretation. I.E. carried out comparative model building. Y.L.-L. and N.M.C. checked all published mutants of A3G and Vif. Y.L.-L. and C.L. created the figures. All authors contributed to data interpretation. Y.L.-L., C.L., I.E., M.E. and J.D.G. wrote the manuscript, with input from all authors.
Peer review
Peer review information
Nature thanks Reuben Harris and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Data availability
Cryo-EM maps and maps focused on specific regions used to guide model building are deposited in the Electron Microscopy Data Bank with accession codes EMD-27032 (A3G–RNA–VCBC monomer), EMD-27033 (A3G–RNA–VCBC dimer for state 1), EMD-27034 (A3G–RNA–VCBC dimer for state 2) and EMD-28667 (A3G–RNA–VCBC dimer for state 1’). The associated coordinate files are deposited in the Protein Data Bank with accession code 8CX0 (A3G–RNA–VCBC monomer), 8CX1 (A3G–RNA–VCBC for state 1) and 8CX2 (A3G–RNA–VCBC for state 2).
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
is available for this paper at 10.1038/s41586-023-05779-1.
Supplementary information
The online version contains supplementary material available at 10.1038/s41586-023-05779-1.
References
- 1.Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–650. doi: 10.1038/nature00939. [DOI] [PubMed] [Google Scholar]
- 2.Harris RS, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803–809. doi: 10.1016/S0092-8674(03)00423-9. [DOI] [PubMed] [Google Scholar]
- 3.Pollpeter D, et al. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G. Nat. Microbiol. 2018;3:220–233. doi: 10.1038/s41564-017-0063-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Delviks-Frankenberry KA, Desimmie BA, Pathak VK. Structural insights into APOBEC3-mediated lentiviral restriction. Viruses. 2020;12:587. doi: 10.3390/v12060587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Uriu K, Kosugi Y, Ito J, Sato K. The battle between retroviruses and APOBEC3 genes: its past and present. Viruses. 2021;13:124. doi: 10.3390/v13010124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Cheng AZ, et al. APOBECs and herpesviruses. Viruses. 2021;13:390. doi: 10.3390/v13030390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 2015;479–480:131–145. doi: 10.1016/j.virol.2015.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Burdick RC, et al. HIV-1 uncoats in the nucleus near sites of integration. Proc. Natl Acad. Sci. USA. 2020;117:5486–5493. doi: 10.1073/pnas.1920631117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Christensen DE, Ganser-Pornillos BK, Johnson JS, Pornillos O, Sundquist WI. Reconstitution and visualization of HIV-1 capsid-dependent replication and integration in vitro. Science. 2020;370:eabc8420. doi: 10.1126/science.abc8420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dharan A, Bachmann N, Talley S, Zwikelmaier V, Campbell EM. Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus. Nat. Microbiol. 2020;5:1088–1095. doi: 10.1038/s41564-020-0735-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 2009;5:e1000330. doi: 10.1371/journal.ppat.1000330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Huthoff H, Malim MH. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 2007;81:3807–3815. doi: 10.1128/JVI.02795-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell. 2003;12:591–601. doi: 10.1016/S1097-2765(03)00353-8. [DOI] [PubMed] [Google Scholar]
- 14.Anderson BD, Harris RS. Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-beta/RUNX axis. Sci. Adv. 2015;1:e1500296. doi: 10.1126/sciadv.1500296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Binning JM, et al. Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors. PLoS Pathog. 2018;14:e1006830. doi: 10.1371/journal.ppat.1006830. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Yu X, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003;302:1056–1060. doi: 10.1126/science.1089591. [DOI] [PubMed] [Google Scholar]
- 17.Khan MA, et al. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 2001;75:7252–7265. doi: 10.1128/JVI.75.16.7252-7265.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004;2:E275. doi: 10.1371/journal.pbio.0020275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Compton AA, Hirsch VM, Emerman M. The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe. 2012;11:91–98. doi: 10.1016/j.chom.2011.11.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Daugherty MD, Malik HS. Rules of engagement: molecular insights from host-virus arms races. Annu. Rev. Genet. 2012;46:677–700. doi: 10.1146/annurev-genet-110711-155522. [DOI] [PubMed] [Google Scholar]
- 21.Etienne L, Hahn BH, Sharp PM, Matsen FA, Emerman M. Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe. 2013;14:85–92. doi: 10.1016/j.chom.2013.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature. 2012;481:376–379. doi: 10.1038/nature10718. [DOI] [PubMed] [Google Scholar]
- 23.Jäger S, et al. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature. 2012;481:371–375. doi: 10.1038/nature10693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kouno T, et al. Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat. Struct. Mol. Biol. 2015;22:485–491. doi: 10.1038/nsmb.3033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Maiti A, et al. Crystal structure of a soluble APOBEC3G variant suggests ssDNA to bind in a channel that extends between the two domains. J. Mol. Biol. 2020;432:6042–6060. doi: 10.1016/j.jmb.2020.10.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Yang H, et al. Understanding the structural basis of HIV-1 restriction by the full length double-domain APOBEC3G. Nat. Commun. 2020;11:632. doi: 10.1038/s41467-020-14377-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hu Y, et al. Structural basis of antagonism of human APOBEC3F by HIV-1 Vif. Nat. Struct. Mol. Biol. 2019;26:1176–1183. doi: 10.1038/s41594-019-0343-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Siu KK, Sultana A, Azimi FC, Lee JE. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun. 2013;4:2593. doi: 10.1038/ncomms3593. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ball KA, et al. Conformational dynamics of the HIV-Vif protein complex. Biophys. J. 2019;116:1432–1445. doi: 10.1016/j.bpj.2019.03.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Compton AA, Malik HS, Emerman M. Host gene evolution traces the evolutionary history of ancient primate lentiviruses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013;368:20120496. doi: 10.1098/rstb.2012.0496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Guo Y, et al. Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif. Nature. 2014;505:229–233. doi: 10.1038/nature12884. [DOI] [PubMed] [Google Scholar]
- 32.Zhang L, et al. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology. 2008;370:113–121. doi: 10.1016/j.virol.2007.08.027. [DOI] [PubMed] [Google Scholar]
- 33.Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 2003;13:2009–2013. doi: 10.1016/j.cub.2003.10.034. [DOI] [PubMed] [Google Scholar]
- 34.Bulliard Y, et al. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 2009;83:12611–12621. doi: 10.1128/JVI.01491-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 2007;81:8201–8210. doi: 10.1128/JVI.00395-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Gallois-Montbrun S, et al. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 2007;81:2165–2178. doi: 10.1128/JVI.02287-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Stenglein MD, Matsuo H, Harris RS. Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol. 2008;82:9591–9599. doi: 10.1128/JVI.02471-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 2006;281:29105–29119. doi: 10.1074/jbc.M601901200. [DOI] [PubMed] [Google Scholar]
- 39.Yamashita T, Kamada K, Hatcho K, Adachi A, Nomaguchi M. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 2008;10:1142–1149. doi: 10.1016/j.micinf.2008.06.003. [DOI] [PubMed] [Google Scholar]
- 40.He Z, Zhang W, Chen G, Xu R, Yu X-F. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 2008;381:1000–1011. doi: 10.1016/j.jmb.2008.06.061. [DOI] [PubMed] [Google Scholar]
- 41.Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 2009;83:1992–2003. doi: 10.1128/JVI.01621-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Chen G, He Z, Wang T, Xu R, Yu X-F. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 2009;83:8674–8682. doi: 10.1128/JVI.00653-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Chaipan C, Smith JL, Hu WS, Pathak VK. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 2013;87:444–453. doi: 10.1128/JVI.00676-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Letko M, et al. Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G. J. Virol. 2013;87:11861–11871. doi: 10.1128/JVI.01944-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.York A, Kutluay SB, Errando M, Bieniasz PD. The RNA binding specificity of human APOBEC3 proteins resembles that of HIV-1 nucleocapsid. PLoS Pathog. 2016;12:e1005833. doi: 10.1371/journal.ppat.1005833. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Tan X, et al. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature. 2007;446:640–645. doi: 10.1038/nature05731. [DOI] [PubMed] [Google Scholar]
- 47.Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49–53. doi: 10.1038/nature13527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Gaba A, Flath B, Chelico L. Examination of the APOBEC3 barrier to cross species transmission of primate lentiviruses. Viruses. 2021;13:1084. doi: 10.3390/v13061084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Letko M, Booiman T, Kootstra N, Simon V, Ooms M. Identification of the HIV-1 Vif and human APOBEC3G protein interface. Cell Rep. 2015;13:1789–1799. doi: 10.1016/j.celrep.2015.10.068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Binning JM, Chesarino NM, Emerman M, Gross JD. Structural basis for a species-specific determinant of an SIV Vif protein toward hominid APOBEC3G antagonism. Cell Host Microbe. 2019;26:739–747. doi: 10.1016/j.chom.2019.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Schröfelbauer B, Chen D, Landau NR. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif) Proc. Natl Acad. Sci. USA. 2004;101:3927–3932. doi: 10.1073/pnas.0307132101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Horn-Ghetko D, et al. Ubiquitin ligation to F-box protein targets by SCF-RBR E3-E3 super-assembly. Nature. 2021;590:671–676. doi: 10.1038/s41586-021-03197-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Albin JS, et al. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F. J. Mol. Biol. 2013;425:1172–1182. doi: 10.1016/j.jmb.2013.01.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Huttenhain R, et al. ARIH2 is a Vif-dependent regulator of CUL5-mediated APOBEC3G degradation in HIV infection. Cell Host Microbe. 2019;26:86–99. doi: 10.1016/j.chom.2019.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Iwatani Y, et al. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl Acad. Sci. USA. 2009;106:19539–19544. doi: 10.1073/pnas.0906652106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.van der Kuyl AC, Berkhout B. The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology. 2012;9:92. doi: 10.1186/1742-4690-9-92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Soros VB, Yonemoto W, Greene WC. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 2007;3:e15. doi: 10.1371/journal.ppat.0030015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Goila-Gaur R, Khan MA, Miyagi E, Strebel K. Differential sensitivity of “old” versus “new” APOBEC3G to human immunodeficiency virus type 1 vif. J. Virol. 2009;83:1156–1160. doi: 10.1128/JVI.01734-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Gradia SD, et al. MacroBac: new technologies for robust and efficient large-scale production of recombinant multiprotein complexes. Methods Enzymol. 2017;592:1–26. doi: 10.1016/bs.mie.2017.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Life_Technologies. Bac-to-Bac™ Baculovirus Expression System, https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-expression/insect-protein-expression/bac-to-bac-baculovirus-expression-system.html (2015).
- 61.Mastronarde DN. SerialEM: a program for automated tilt series acquisition on Tecnai microscopes using prediction of specimen position. Microsc. Microanal. 2003;9:1182–1183. doi: 10.1017/S1431927603445911. [DOI] [Google Scholar]
- 62.de la Rosa-Trevin JM, et al. Scipion: a software framework toward integration, reproducibility and validation in 3D electron microscopy. J. Struct. Biol. 2016;195:93–99. doi: 10.1016/j.jsb.2016.04.010. [DOI] [PubMed] [Google Scholar]
- 63.Zheng SQ, et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods. 2017;14:290–296. doi: 10.1038/nmeth.4169. [DOI] [PubMed] [Google Scholar]
- 65.Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Bai XC, Rajendra E, Yang G, Shi Y, Scheres SH. Sampling the conformational space of the catalytic subunit of human gamma-secretase. eLife. 2015;4:e11182. doi: 10.7554/eLife.11182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Goddard TD, Huang CC, Ferrin TE. Visualizing density maps with UCSF Chimera. J. Struct. Biol. 2007;157:281–287. doi: 10.1016/j.jsb.2006.06.010. [DOI] [PubMed] [Google Scholar]
- 68.Scheres SH. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 2012;180:519–530. doi: 10.1016/j.jsb.2012.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Punjani A, Fleet DJ. 3D variability analysis: resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. J. Struct. Biol. 2021;213:107702. doi: 10.1016/j.jsb.2021.107702. [DOI] [PubMed] [Google Scholar]
- 70.Rosenthal PB, Henderson R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 2003;333:721–745. doi: 10.1016/j.jmb.2003.07.013. [DOI] [PubMed] [Google Scholar]
- 71.Sanchez-Garcia R, et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 2021;4:874. doi: 10.1038/s42003-021-02399-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Terwilliger TC, Ludtke SJ, Read RJ, Adams PD, Afonine PV. Improvement of cryo-EM maps by density modification. Nat. Methods. 2020;17:923–927. doi: 10.1038/s41592-020-0914-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Kucukelbir A, Sigworth FJ, Tagare HD. Quantifying the local resolution of cryo-EM density maps. Nat. Methods. 2014;11:63–65. doi: 10.1038/nmeth.2727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Tan YZ, et al. Addressing preferred specimen orientation in single-particle cryo-EM through tilting. Nat. Methods. 2017;14:793–796. doi: 10.1038/nmeth.4347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Asarnow, D., Palovcak, E. & Cheng, Y. asarnow/pyem:UCSF pyem v0.5. Zenodo https://zenodo.org/record/3576630#.Y-Tme3bP3IU (2019).
- 76.Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993;234:779–815. doi: 10.1006/jmbi.1993.1626. [DOI] [PubMed] [Google Scholar]
- 77.Webb B, Sali A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinformatics. 2016;54:5.6.1–5.6.37. doi: 10.1002/cpbi.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
- 79.Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010;66:486–501. doi: 10.1107/S0907444910007493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Croll TI. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D Struct. Biol. 2018;74:519–530. doi: 10.1107/S2059798318002425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010;66:213–221. doi: 10.1107/S0907444909052925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Afonine PV, et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D Struct. Biol. 2018;74:531–544. doi: 10.1107/S2059798318006551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Mostosi P, Schindelin H, Kollmannsberger P, Thorn A. Haruspex: a neural network for the automatic identification of oligonucleotides and protein secondary structure in cryo-electron microscopy maps. Angew. Chem. Int. Ed. Engl. 2020;59:14788–14795. doi: 10.1002/anie.202000421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Chou FC, Sripakdeevong P, Dibrov SM, Hermann T, Das R. Correcting pervasive errors in RNA crystallography through enumerative structure prediction. Nat. Methods. 2013;10:74–76. doi: 10.1038/nmeth.2262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 2010;66:12–21. doi: 10.1107/S0907444909042073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Afonine PV, et al. New tools for the analysis and validation of cryo-EM maps and atomic models. Acta Crystallogr. D Struct. Biol. 2018;74:814–840. doi: 10.1107/S2059798318009324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Pintilie G, et al. Measurement of atom resolvability in cryo-EM maps with Q-scores. Nat. Methods. 2020;17:328–334. doi: 10.1038/s41592-020-0731-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Young J, Garikipati N, Durrant JD. BINANA 2: characterizing receptor/ligand interactions in Python and JavaScript. J. Chem. Inf. Model. 2022;62:753–760. doi: 10.1021/acs.jcim.1c01461. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res. 2015;43:W443–W447. doi: 10.1093/nar/gkv315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 2011;51:2778–2786. doi: 10.1021/ci200227u. [DOI] [PubMed] [Google Scholar]
- 91.Schrödinger, L. & DeLano, W. L. PyMOL. http://www.pymol.org/pymol (2020).
- 92.Goddard TD, et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 2018;27:14–25. doi: 10.1002/pro.3235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Shen MY, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci. 2006;15:2507–2524. doi: 10.1110/ps.062416606. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Kostrhon S, et al. CUL5-ARIH2 E3-E3 ubiquitin ligase structure reveals cullin-specific NEDD8 activation. Nat. Chem. Biol. 2021;17:1075–1083. doi: 10.1038/s41589-021-00858-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. Genome Res. 2004;14:1188–1190. doi: 10.1101/gr.849004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 2014;42:W320–W324. doi: 10.1093/nar/gku316. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Cryo-EM maps and maps focused on specific regions used to guide model building are deposited in the Electron Microscopy Data Bank with accession codes EMD-27032 (A3G–RNA–VCBC monomer), EMD-27033 (A3G–RNA–VCBC dimer for state 1), EMD-27034 (A3G–RNA–VCBC dimer for state 2) and EMD-28667 (A3G–RNA–VCBC dimer for state 1’). The associated coordinate files are deposited in the Protein Data Bank with accession code 8CX0 (A3G–RNA–VCBC monomer), 8CX1 (A3G–RNA–VCBC for state 1) and 8CX2 (A3G–RNA–VCBC for state 2).